GenVec plunges on failure of TNFerade in Phase III pancreatic cancer trial
This article was originally published in Scrip
GenVec has discontinued its Phase III clinical trial of its lead gene therapy product TNFerade in patients with locally advanced pancreatic cancer after an interim analysis showed it would not improve survival. Shares in GenVec plunged by 70% to under a dollar in early morning trading on Nasdaq on 30 March on the news.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.